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Abstract
AIM
To investigate the effect and mechanism of moxibustion 
in rats with ulcerative colitis.
METHODS
A rat colitis model was established by administering 4% 
dextran sulphate sodium solution. Seventy male rats were 
randomly divided into seven groups: Healthy controls 
(HC), ulcerative colitis model group (UC), UC with 7 d of 
moxibustion (UC-7), UC with 14 d of moxibustion (UC-14), 
UC with mesalazine gavage (UC-W), HC with 7 d of moxi-
bustion (HC-7), HC with 14 d of moxibustion (HC-14). 
Moxibustion was applied to the bilateral Tianshu (ST25). 
Gut microbiome profiling was conducted by 16S rRNA 
amplicon sequencing, and PCR and ELISA determined the 
expression of inflammatory cytokines in colon mucosa and 
serum, respectively. 
RESULTS
Moxibustion treatment restored the colonic mucosa and 
decreased submucosal inflammatory cell infiltration in 
colitis rats. Rats treated with moxibustion and mesa-
lazine had significantly lower levels of the dominant 
phyla Proteobacteria and the genera Saccharibacteria , 
Sphingomonas  and Barnesiella  than colitis rats, and 
they could restore the microbiome to levels similar to 
those observed in healthy rats. UC rats had reduced 
alpha diversity, which could be alleviated by moxibustion 
therapy, and UC-7 had a higher alpha diversity than 
UC-14. This finding suggests that short-term (7 d) but 
no longer term (14 d) moxibustion treatment may signifi-
cantly affect the gut microbiome. The potential bacterial 
functions affected by moxibustion may be ascorbate 
and aldarate metabolism, and amino acid metabolism. 
Compared with HC group, the levels of the cytokines 
interleukin-12 (IL-12) (P  < 0.05) and IL-6, IL-17, IL-23, 
interferon-γ, lipopolysaccharide, IgA, tumour necrosis 
factor-α and its receptors 1 (TNFR1) and TNFR2 (P  < 0.01) 
were all increased, whereas anti-inflammatory cytokine 
IL-2 and IL-10 (P  < 0.01) and transforming growth 
factor-β (P  < 0.05) were decreased in UC rats. These 
changes were reversed by moxibustion.
CONCLUSION
Our findings suggest that moxibustion exerts its thera-
peutic effect by repairing mucosal tissue damage and 
modulating the gut microbiome and intestinal mucosal 
immunity.
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Core tip: Ulcerative colitis (UC) is a form of inflammatory 
bowel disease and microbial dysbiosis is an important 
pathological factor of UC. Moxibustion treatment can repair 
mucosal tissue damage and regulate immune function in 
patients with UC associated with gut microbiome changes. 
In this study, moxibustion can significantly reduce the 
colonic tissue damage and the levels of pro-inflammatory 
cytokines and anti-inflammatory cytokines in rats with 4% 
dextran sulphate sodium-induced ulcerative colitis, relieve 
intestinal inflammation, and promote the restoration of 
impaired colonic tissue. In addition, moxibustion can in-
crease the diversity of the gut microbiome and the UC 
with 7 d of moxibustion had a higher alpha diversity than 
UC with 14 d of moxibustion.
Qi Q, Liu YN, Jin XM, Zhang LS, Wang C, Bao CH, Liu HR, 
Wu HG, Wang XM. Moxibustion treatment modulates the 
gut microbiota and immune function in a dextran sulphate 
sodium-induced colitis rat model. World J Gastroenterol 2018; 
24(28): 3130-3144  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v24/i28/3130.htm  DOI: http://dx.doi.
org/10.3748/wjg.v24.i28.3130
INTRODUCTION
The gut microbiome has been referred to as a “forgotten 
organ”[1] due to its capacity to influence host physiology. 
The gut microbiome is incredibly diverse, with dominant 
phyla including Firmicutes, Bacteroidetes, Proteobacteria, 
Verrucomicrobia, Actinobacteria and Fusobacteria[2,3]. 
Gut microbiome composition varies substantially among 
individuals and is thought to be a key determinant of 
susceptibility to several diseases[4-6]. The gut microbiome 
provides signals that promote immune cell maturation 
and ensure the normal development of immune func­
tion[7], which is crucial for human life and profoundly inf­
luences human physiology and metabolism[8,9].
Ulcerative colitis (UC) is a form of inflammatory bow­
el disease that can lead to bloody diarrhoea, passage 
of pus and/or mucus, and abdominal cramping during 
bowel movements[10,11]. Immune dysfunction plays a key 
role in driving inflammatory responses during UC devel­
opment and progression. UC is commonly treated with 
therapeutics such as the anti­inflammatory drugs mesa­
lazine and sulphasalazine, with steroid enemas[12] or with 
surgical intervention. The aetiology and pathogenesis 
of UC have not been fully elucidated but are thought to 
result from detrimental interactions among intestinal 
microbiota, the gut epithelium, and the host immune 
system in genetically susceptible individuals[13,14]. Several 
studies have recently reported decreased gut microbial 
diversity in patients with active UC[15,16]. Microbial dys­
biosis is an important pathological factor of UC that 
affects host mucosal immunity[17­19]. Pathogenic bacteria 
and opportunistic pathogens interact with the intestinal 
mucosa directly or indirectly via secreted toxins, which 
may lead to an inappropriate intestinal mucosal immune 
response.
Studies have demonstrated that moxibustion, a 
traditional Chinese therapy that treats and prevents 
diseases using moxa (floss of Artemisia argyi), is a 
safe and effective treatment for UC[20­23]. Moxibustion 
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exerts its therapeutic effects by regulating immune 
function[24,25], apoptosis[26,27], and protein expression at 
acupuncture points and in colon tissues[28,29]. UC is asso­
ciated with changes in the gut microbiome, and moxi­
bustion modulates the imbalance of intestinal flora[30]. 
Nevertheless, the gut microbiome is a complex com­
munity with only a small proportion of culturable orga­
nisms, and the effect of moxibustion on the gut micro­
biome remains unknown. Recently developed culture­
independent high­throughput sequencing methods allow 
gut microbiome profiling and assessments of microbial 
gene abundance and community structure to be per-
formed more easily[31].
Here, we used 16S rRNA gene sequencing to assess 
the gut microbial composition and community structure 
in faecal samples of UC rats treated with moxibustion 
or mesalazine gavage. Our aims were to determine the 
impact of moxibustion on intestinal microbial community 
structure, the role of the intestinal microbiota in UC patho­
genesis, and the molecular mechanism underlying the 
effect of moxibustion in UC treatment.
MATERIALS AND METHODS
Rats and groups
Seventy specific pathogen­free male Sprague Dawley 
rats (body weight 180­220 g) were provided by the 
Department of Laboratory Animal Science of Fudan 
University (Shanghai Slack Laboratory Animal Co., 
LTD. license: SCXK (Shanghai) 2012­0002 and SYXK 
(Shanghai) 2009­0082). All rats were raised under 
standard conditions: 25 ± 1 ℃, 50%­70% humidity, and 
12 h light/dark cycle. Rats were allowed to acclimatize 
for one week before the start of the trial. Rats (n = 70) 
were divided into seven groups: healthy controls (HC), 
healthy controls with seven days of moxibustion (HC­7), 
healthy controls with fourteen days of moxibustion 
(HC­14), UC model group (UC), UC model with seven 
days of moxibustion (UC­7), UC model with fourteen 
days of moxibustion (UC­14), and UC model with 
mesalazine gavage (UC­W). UC was induced with 4% 
dextran sulphate sodium (DSS; molecular weight: 
36000­50000 Da; Art.No.9011­18­1; MP Biomedicals) 
supplied in drinking water. Animal breeding, care and all 
experiments were performed according to procedures 
approved by the University Animal Care and Use Com­
mittee of Shanghai University of Traditional Chinese 
Medicine (IACUC protocol number: SYXK (shanghai) 
2009­0082) to relieve pain and avoid injury. All protocols 
were performed in strict accordance with the Guidance 
Suggestions for the Care and Use of Laboratory Animals, 
as formulated by the Ministry of Science and Technology 
of the People’s Republic of China[32]. We tried all efforts to 
minimize animal suffering. 
DSS-induced-colitis
UC was induced with 4% DSS in drinking water for 
seven consecutive days as described previously[33]. After 
seven days, two rats were randomly selected to confirm 
successful establishment of the animal model. Rats 
were provided 1% DSS in the drinking water for seven 
consecutive days in the UC, UC­7 and UC­W groups and 
fourteen consecutive days in the UC­14 group.
Treatment
For the HC­7 (n = 10) and UC­7 (n = 10) groups, moxa 
cones (0.5 cm in diameter and 0.6 cm high) (Nanyang 
Hanyi Moxa Co., Ltd. China) were placed on the herb 
cake, and the herb cake was placed on Tianshu (ST25, 
bilateral) with moxibustion for 10 min once a day for 
seven days, the herb cakes were prepared with Chinese 
medicine powder and yellow wine into size of 1.0 cm in 
diameter and 0.5 cm in thickness, and the skin tempe­
rature of acupuncture points was 43 ± 1 ℃. ST25 is 5 mm 
lateral to anterior midline at the navel level[34]. The HC­14 
(n = 10) and UC­14 (n = 10) groups received the same 
treatment as the HC­7 and UC­7 groups, respectively, 
but for fourteen days. The UC­W group (n = 10) received 
mesalazine enteric­coated tablets (Heilongjiang Tianhong 
Pharmaceutical Co., Ltd; Lot number: H20103359) by 
gavage administration twice daily for seven consecutive 
days with a dose calculated from that specified for an 
adult of 70 kg and a weight ratio of 1:0.018 for rats (200 
g). The HC (n = 10) and UC (n = 10) groups did not 
receive any treatment but received the same fixation (to 
fix the hands and feet on the fixed mount).
Sample collection and processing
Following treatment, rats were anaesthetized via intra-
peritoneal injection with 2% pentobarbital sodium 
for tissue collection. Blood samples were collected by 
abdominal aortic, after one hour standing, the samples 
were centrifuged at 3000 rpm for ten minutes at 4 ℃ 
to separate the plasma. The obtained plasma was 
stored at -80 ℃. Colon samples were rapidly removed 
and separated from the large intestine (6 cm distal to 
the anus). Then, 5 g of faecal matter was collected in 
cryogenic vials and stored at ­80 ℃. Colon samples 
were flushed with physiological saline to remove the 
surrounding connective tissue and fat. Colonic mucosal 
injury was observed with the naked eye. Then, the 
colon was divided into two segments: one segment was 
fixed in 10% paraformaldehyde for haematoxylin and 
eosin (HE) staining for histological observation and the 
histological grade was scored with the bland method[30] 
(Table 1), whereas the other segment was stored at 
-80 ℃.
Haematoxylin and eosin staining
Colon samples fixed with 10% paraformaldehyde were 
dehydrated and immersed in wax using an automatic 
tissue dehydrating machine, embedded in paraffin and 
sectioned at 4 μm thickness with a microtome. Slices 
were incubated with xylene Ⅰ and Ⅱ for 20 min each 
and rehydrated in absolute alcohol, 95% alcohol, 85% 
alcohol and 75% alcohol (3 min each time). Slices were 
stained with haematoxylin for 1 min, followed by 1% 
hydrochloric acid­alcohol for 30 s, and counterstained 
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tion of Unobserved States (PICRUSt 1.0.0)[37] was used 
to predict metagenome function from the 16S rRNA data. 
Statistical Analysis of Metagenomic Profiles (STAMP)[38] 
was used to analyse the predicted metagenome and to 
identify pathways associated with UC. The Benjamini­
Hochberg procedure was used to control the false discov­
ery rate due to multiple testing. 
PCR analysis
Total RNA was isolated using TRIzol® LS (Invitrogen 
Corp.) according to the manufacturer’s instructions. The 
integrity of the RNA samples was assessed via agarose 
gel (10 g/L) electrophoresis, and RNA concentrations 
were determined using a NanoDrop ND­2000 Spectro­
photometer (Thermo Electron Corporation). Two micro­
grams of total RNA was used for RT­PCR in a 20 μL 
reverse transcription reaction system. Two micrograms 
of RNA, up to 8 μL of DEPC, 0.5 μL (50 U/μL) of RNase 
inhibitor and 2 μL of oligomer (dT)15 and primer were 
mixed and placed in a 65 ℃ water for 5 min. Then, the 
mixture was placed at room temperature for 10 min. 
After a 5 s centrifugation, the following reagents were 
added to the reactions: 0.5 μL (50 U/μL) of RNase 
inhibitor, 4 μL of 5 × RT buffer solution, 2 μL of dNTPs (10 
mmol/L for each), 2 μL of DTT, and 1 μL of AMV reverse 
transcriptase (200 U/μL). The solution was mixed and 
placed in water at 40 ℃ for 1 h, heated to 90 ℃ in water 
for 5 min, and centrifuged for 5 s.
The primers used were designed with Primer Express 
Software v2.0 (Applied Biosystems, United States) and 
synthesized at the Beijing Genomics Institute. Gene 
sequences of the primers are presented in Table 2.
Each 16 μL PCR included: 8 μL of 2 × SYBR Green 
PCR mix, 1 μL of each sense and antisense primer, 1 
μL of reverse transcription product (cDNA), and 5 μL of 
H2O. RT­PCR was performed using a ViiA 7 Real Time 
PCR System (Applied Biosystems, United States). The 
reaction conditions were set at 95 ℃ for 2 min, 94 ℃ for 
10 s, 60 ℃ for 10 s, and 72 ℃ for 40 s for 40 cycles.
ELISA analysis
The levels of interleukin­2, 10, 12, 17, 23, interferon­γ 
(IFN­γ), lipopolysaccharide (LPS), immunoglobulin A 
(IgA), transforming growth factor­β (TGF­β), tumour 
necrosis factor-α (TNF­α), TNF receptor 1 (TNFR1) and 
TNFR2 in all serum samples were tested by sandwich 
ELISA. According to manufacturer’s instructions, IL­2, 
IL­10, IL­12, 17, IL­23, IFN­γ, LPS, IgA, TGF­β, TNF­α, 
TNFR1 and TNFR2 were measured using corresponding 
ELISA kits (Biotech well, Shanghai, China). The detection 
limits were: 17 pg/mL for IL­2, IL­12, IL­23, and TNF­α, 
16 pg/mL for IL­10, 15 pg/mL for IL­17, and TGF­β, 12 
pg/mL for IFN­γ, 8 pg/mL for LPS, 8ng/mL for IgA, 6 pg/
mL for TNFR1, and 5 pg/mL for TNFR2.
Statistical analysis
Differential abundance testing between groups was 
performed using the Kruskal­Wallis test in R 3.2.3 (http://
cran.r­project.org). Alpha diversity was measured with 
with eosin for 5 min. Sample histology was observed by 
electron microscope.
Bacterial genomic DNA extraction
Genomic DNA was extracted from faecal samples using 
the QIAamp DNA Mini Kit (QIAGEN, Germany). Briefly, 20 
μL of proteinase K solution (20 mg/mL) and 100 mg of 
zirconium beads (0.1 mm) were added to the pellet. The 
mixture was agitated three times with a Mini­Beadbeater 
(FastPrep, Thermo Electron Corporation, United States); 
buffer AL was added to the mixture, which was then 
incubated for 10 min at 70 ℃. Next, 200 μL of ethanol 
(96%) was added. This mixture was then loaded onto a 
QIAamp Mini spin column and centrifuged at 8000 g for 
1 min. The column material was washed with the first 
washing buffer (buffer AW1, 500 μL) followed by the 
second washing buffer (buffer AW2, 500 μL) provided 
with the kit. Finally, DNA was eluted with 100 μL of 
buffer AE. DNA integrity was assessed by electrophoresis 
on a 1% agarose gel containing 0.5 mg/mL ethidium 
bromide. DNA concentrations were determined using a 
NanoDrop ND­2000 spectrophotometer (Thermo Elec­
tron Corporation).
Illumina sequencing and data processing
The 16S rRNA gene hypervariable V3­V4 region was 
amplified by PCR using the barcode­tag universal 
bacterial modified primers. The prototype primers were 
341F (5’­ACTCCTACGGGAGGCAGCAG­3’) and 806R 
(5’­GGACTACVVGGGTATCTAATC­3’). Amplicon sequen­
cing was performed using Illumina MiSeq (PE300). Raw 
reads were demultiplexed and filtered according to read 
length and quality. Chimeric reads were removed, and 
OTU selection was performed as previously described[35]. 
The filtered reads were dereplicated to unique sequences 
and sorted by abundance before being subjected to OTU 
clustering at 97% similarity. Taxonomy was assigned 
to the representative sequence of each OTU using the 
Ribosomal Database Project classifier[36]. 
Prediction of metagenome functional content
Phylogenetic Investigation of Communities by Reconstruc­
Histopathological manifestation score
Ulcer No ulcer 0
Ulcer area < 3 cm 1
Ulcer area > 3 cm 2
Inflammation No inflammation 0
Mild inflammation 1
Severe inflammation 2
Granuloma No granuloma 0
Granuloma 1
Lesion depth No lesion 0
Submucosa 1
Muscular layer 2
Serosa layer 3
Fibrosis No fibrosis 0
Mild fibrosis 1
Severe fibrosis 2
Table 1  Histopathological Scores
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Simpson and Shannon diversity indices. Beta diversity 
was determined using unweighted unifrac distance and 
was summarized by PCoA. A principal components ana­
lysis (PCA) plot of Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) modules with significant differences in 
mean proportion differences was created using STAMP[39] 
(v2.1.3). Body weight gain, RT­PCR and ELISA analysis 
data are presented as the mean ± SD. Histopathological 
score data are expressed as M (Q25­Q75). ANOVA and 
Least Significant Difference multiple comparison tests 
were performed using IBM SPSS statistics 21.0 (IBM Co., 
Armonk, NY, United States). P < 0.05 was considered 
significant.
RESULTS
Body weight gains in different groups 
Two rats in the UC­W group died after gavage during 
the experiment. The body weight gain in the UC group 
was lower than that in the HC group (P < 0.01). After 
treatment, the body weight gains in the UC­7, UC­14, 
HC­7, HC­14 (P < 0.01) and UC­W (P < 0.05) groups 
were higher than that in the UC group (Figure 1).
Changes in the colon histopathology 
Rat colons were observed by light microscopy (Figure 
2). The HC, HC­7, and HC­14 groups had similar 
histopathologies, with intact colonic mucosal epithelia, 
regularly arranged glands, and evenly distributed me­
senchyme. No congestion, oedema, ulcers or other 
pathological abnormalities were noted. By contrast, UC 
rats exhibited colonic mucosa damage, with a reduced 
number of glands and substantial inflammatory cell 
infiltration in the mucosa and submucosa. These abnor­
malities could be alleviated by moxibustion treatment, 
which restored the colonic mucosa to the level of healthy 
rats, and decreased submucosal inflammatory cell infil­
tration and congestion in the UC­7 and UC­14 groups. 
However, in the UC­W group, mucosal and submucosal 
glands were disorganized, with abundant inflammatory 
cell infiltration. The histopathological scores for the colon 
tissues in the different groups are presented in Figure 
3. The histopathological scores in the UC group were 
significantly higher than those in the HC group (P < 0.01). 
After treatment, the scores were decreased in the UC­7, 
UC­14, UC­W, HC­7 and HC­14 groups compared with 
those in the UC group (P < 0.01).
Core bacteria
Approximately 3.9 million high­quality (> 220 bp) se­
quence reads were obtained using the MiSeq system 
(Illumina, San Diego, CA, United States), which led to the 
identification of 1545 operational taxonomic units (OTUs), 
with an average read length of 451.58 bp. Overall, the 
Target gene Forward sequence Reverse sequence
IL-6 GCCAGAGTCATTCAGAGCAA TTGGTCCTTAGCCACTCCTT
IL-10 CTGTCATCGATTTCTCCCCT CAAACTCATTCATGGCCTTG
IL-12 CCCTCAAGTTCTTCGTCCGC TTTGCATTGGACTTCGGCAG
IL-17 ATCCAGCAAGAGATCCTGGT CAATAGAGGAAACGCAGGTG
IL-23 TGTGGTGATGGTTGTGATCC TGTGAAGATGTCCGAGTCCA
TNF-α GAAAGCATGATCCGAGATGT CAGGAATGAGAAGAGGCTGA
TNFR1 TGAGACGCATTTCCAGTGTG AGAATCCTGCGTGGCAGTTA
TNFR2 CATGTCAACGTCACCTGCAT TCATCCTTTGGAGACCCTGA
rACTIN ACTTCGAGCAGGAGATGGCC CCCAGGAAGGAAGGCTGGAA
Table 2  Primer sequences
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Figure 1  Body weight gains after treatment in different groups. HC: Healthy controls; UC: UC model group; UC-7: UC model with seven days of moxibustion; 
UC-14: UC model with fourteen days of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with seven days of moxibustion; HC-14: 
healthy controls with fourteen days of moxibustion. The body weight gain in the UC group was decreased compared with the HC group (P < 0.01). After treatment, the 
body weight gains in the UC-7, UC-14, HC-7, HC-14 (P < 0.01) and UC-W (P < 0.05) groups were increased compared with the UC group. bP < 0.01 vs the HC group; 
cP < 0.05, dP < 0.01 vs the UC group.
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relative abundance levels of 18 dominant phyla were 
identified in the entire model system. Among these 
phyla, five (Firmicutes, Bacteroidetes, Proteobacteria, 
Candidatus Saccharibacteria, and Actinobacteria) were 
present at ≥ 1% and were the dominant phyla in all 
groups, but relative abundance varied by treatment. A 
total of 186 families were detected, and 100 families 
were commonly present, of which Lachnospiraceae, 
Ruminococcaceae, Porphyromonadaceae, Lactobacil­
laceae, Sphingomonadaceae, Veillonellaceae and Corio­
bacteriaceae were the dominant families detected. A 
total of 325 OTUs were identified at the genus level, 
of which 10 core OTUs were present in all groups. The 
highest average number of OTUs identified at the genus 
level (134) was detected in the UC­14 rats, whereas the 
lowest (78) was found in HC rats. As shown in Figure 4, 
the UC group had the most unique genera, even after 
treatment with either moxibustion or mesalazine gavage.
Community abundance variation between healthy 
controls and UC model rats
There were significant differences in the microbiome 
HC UC UC-7
UC-14 UC-W HC-7
HC-14
Figure 2  Rat colon tissue pathology under different treatments. HC: Healthy controls; UC: UC model group; UC-7: UC model with seven days of moxibustion; 
UC-14: UC model with fourteen days of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with seven days of moxibustion; HC-14: 
Healthy controls with fourteen days of moxibustion. The colonic mucosa in HC, HC-7, and HC-14 rats exhibited no pathological abnormalities. The colonic mucosa 
was damaged in the UC group, with a reduction in the number of glands and cell infiltration. After moxibustion treatment, decreased cell infiltration and congestion 
were noted in the UC-7 and UC-14 groups. Glands were disorganized with abundant inflammatory cell infiltration in the UC-W group. Red arrow indicated inflammatory 
cell infiltration and green arrow indicate gland (magnification: 200 ×).
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Figure 3  Histopathological scores for colon tissue in the different groups. 
HC: Healthy controls; UC: UC model group; UC-7: UC model with seven days 
of moxibustion; UC-14: UC model with fourteen days of moxibustion; UC-W: 
UC model with mesalazine gavage; HC-7: Healthy controls with seven days of 
moxibustion; HC-14: Healthy controls with fourteen days of moxibustion. The 
histopathological scores in the UC group were significantly increased compared 
with the HC group (P < 0.01). After treatment, the scores were decreased in the 
UC-7, UC-14, UC-W, HC-7 and HC-14 groups compared with the UC group (P 
< 0.01). bP < 0.01 vs the HC group; dP < 0.01 vs the UC group.
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between healthy controls and UC rats. Although Firmi­
cutes was the predominant phylum in all samples, 
UC rats had increased relative abundance levels of 
Proteobacteria, Candidatus and Saccharibacteria and 
decreased relative abundance levels of Firmicutes and 
Actinobacteria compared with HC rats. At the family 
level, UC rats had decreased Lactobacillaceae and 
Ruminococcaceae and increased Sphingomonadaceae, 
Pseudomonadaceae and Porphyromonadaceae (Figure 
5B). In addition, Lactobacillus, Clostridium ⅩⅣa and 
Ruminococcus were increased and Saccharibacteria and 
Sphingomonas were decreased in HC compared with UC 
rats (Figure 5C). UC rats had lower alpha diversity than 
HC rats, and the Shannon Diversity Index was reduced 
(Figure 5D), consistent with previous reports[15,40]. 
Community abundance variations between healthy 
controls with or without moxibustion treatment
In HC­7 and HC­14 groups, Firmicutes were decreased 
and Bacteroidetes and Proteobacteria were increased 
compared with the HC group (Figure 5A). At the 
family level, Porphyromonadaceae was increased 
and Ruminococcaceae and Veillonellaceae were de­
creased in moxibustion­treated groups (Figure 5B). 
Compared with the HC­7 group, the HC­14 group 
had increased abundance levels of Lachnospiraceae 
and Ruminococcaceae and a decreased abundance 
of Lactobacillaceae. At the genus level, Lactobacillus 
and Desulfovibrio were significantly increased, and 
Ruminococcus and Barnesiella were significantly de­
creased in both HC­7 and HC­14 groups relative to 
HCs. In particular, significant differences between HC­7 
and HC­14 were noted regarding the abundance levels 
of Lactobacillus, Saccharibacteria, and Blautia. HC­7 
exhibited increased abundance levels of Lactobacillus and 
Blautia and a reduced abundance of Saccharibacteria 
compared with those in the HC­14 group. Lactobacillus 
and Pseudomonas were significantly enriched in HC­7 (but 
not HC­14) compared with the HC group. Interestingly, 
Saccharibacteria was decreased in HC­7 but increased 
in HC­14 compared with HCs (Figure 5C). It is not clear 
why the alpha diversity was decreased in HC­7 but 
increased in HC­14 compared with HCs (Figure 5D).
Community abundance variations between UC groups 
with or without moxibustion treatment
Moxibustion treatment (but not mesalazine gavage) 
for seven days or fourteen days was associated with 
an increase in Firmicutes compared with the UC 
group, whereas Proteobacteria and Candidatus and 
Saccharibacteria were decreased to varying degrees 
in both the moxibustion­ and mesalazine­treated 
groups compared with the UC group. Bacteroidetes 
was reduced in UC­14 but substantially increased 
in the UC­W group compared with the UC group 
(Figure 5A). At the family level, UC­7 was similar to 
UC­W but significantly different from UC­14. UC­14 
exhibited increased Sphingomonadaceae and de-
creased Porphyromonadaceae compared with UC­7 
and UC­W. Coriobacteriaceae, Pseudomonadaceae 
and Bifidobacteriaceae were significantly reduced in 
UC­7, UC­14 and UC­W groups compared with the UC 
group (Figure 5B). UC­14 had relatively low levels of 
Lactobacillus but relatively high levels of Clostridium 
XIVa and Sphingomonas with a dominant position in 
all groups. In the UC­W group, Saccharibacteria was 
decreased and Barnesiella, Prevotella, and Alloprevotella 
were increased significantly compared with all of the 
other groups (Figure 5C).
Biodiversity and microbial richness
Alpha diversity was estimated through rarefaction 
analysis and the Shannon and Chao1 indexes. The 
lowest OTU richness was observed in the HC groups. 
Multiple rarefaction curves analysis indicated variation 
among samples and exhibited sufficient data coverage 
for diversity in the samples. The Shannon Wiener 
index showed the lowest value of evenness in HC rats. 
Surprisingly, HC­7 also showed a lower value. Interest­
ingly, after seven days of treatment with moxibustion, 
the genus level diversity was comparable to that of HCs 
but notably different from the UC­14 and UC­W groups. 
UC­7 and UC­W had the highest median alpha diversity, 
which was restored to the normal level of HC and HC­14 
(Figure 5D). This finding suggests that both moxibustion 
treatment and mesalazine gavage increased colonic 
microbial diversity. In terms of beta­diversity, UC samples 
clustered separately from HC samples in a principal 
coordinates analysis (PCoA), indicating that disease state 
was the primary factor influencing community differences 
(Figure 6). UC ­7 was more similar to UC­W on the first 
axis, whereas HC­7 and HC­14 were more similar to HC 
and UC­14. Using non­metric multidimensional scaling 
(nMDS) instead of PCoA produced similar results (Figure 
7).
Core 10
UC-W UC-14
UC-7
UC
HC
HC-14
28 16
28
864
HC-7
7
Figure 4  Summary of operational taxonomic units identified at the genus 
level in each group. HC: Healthy controls; UC: UC model group; UC-7: UC 
model with seven days of moxibustion; UC-14: UC model with fourteen days of 
moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls 
with seven days of moxibustion; HC-14: Healthy controls with fourteen days of 
moxibustion. There were ten core operational taxonomic units in all groups. The 
UC group had the most unique genera.
9
Qi Q et al . Moxibustion modulates gut microbiota in colitis
3137 July 28, 2018|Volume 24|Issue 28|WJG|www.wjgnet.com
Genus level differences among treatment groups
To establish which taxa were contributing most to 
the apparent differences in diversity between groups, 
genus level abundance was assessed. Saccharibacteria, 
Ruminococcus, Sphingomonas, Pseudomonas, 
Clostridium Ⅳ, Prevotella and Alloprevotella were the 
most affected genera (Figure 8). These opportunistic 
pathogens can cause infection and may be important 
contributing factors in UC pathogenesis. Indeed, both 
Bacteroidetes[41] and Clostridium Ⅳ[42] are associated with 
UC. In our study, we found that UC rats had a higher 
density of Bacteroidetes and reduced Clostridium Ⅳ 
compared with the control.
Predictive functional profiling of microbial communities 
Community function was inferred from 16S composi­
tional data using PICRUSt. In the KEGG pathway 
analysis, ascorbate and aldarate metabolism were sig­
nificantly increased in both UC and HC rats treated with 
moxibustion for fourteen days (Supplement Table 1), 
which suggests that long­term moxibustion treatment 
could increase ascorbate and aldarate metabolism. 
Furthermore, compared with the HC group, the HC­7 
and HC­14 groups had significant increases in genes 
belonging to the amino acid metabolism pathway. Com­
pared with the UC group, these genes were increased 
in the UC­7 and UC­14 groups, but no significant dif­
ferences were noted. However, the roles of these meta­
bolic pathways in UC are unclear.
Levels of IL-6, IL-10, IL-12, IL-17, IL-23, TNF-α, TNFR1 
and TNFR2 mRNA in colon mucosa
IL­6, IL­17, IL­23, TNF­α, TNFR1 and TNFR2 (P < 
0.01) and IL­12 mRNA (P < 0.05) exhibited significant 
Qi Q et al . Moxibustion modulates gut microbiota in colitis
Figure 5  Comparative analyses of the dominant phyla, families and genera under different treatments. HC: Healthy controls; UC: UC model group; UC-7: 
UC model with seven days of moxibustion; UC-14: UC model with fourteen days of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls 
with seven days of moxibustion; HC-14: Healthy controls with fourteen days of moxibustion. A: The relative abundance levels of Proteobacteria, Candidatus, and 
Saccharibacteria were increased, whereas Firmicutes and Actinobacteria were decreased in the UC group compared with the HC group. These changes in microbiota 
profiles could be reversed by moxibustion treatment for seven days or fourteen days; B: UC rats had decreased Lactobacillaceae and Ruminococcaceae and 
increased Sphingomonadaceae, Pseudomonadaceae, and Porphyromonadaceae compared with the HC group. After treatment, Pseudomonadaceae was reduced in 
the UC-7, UC-14 and UC-W groups compared with the UC group; C: Lactobacillus, Clostridium XlVa, and Ruminococcus were increased and Saccharibacteria and 
Sphingomonas were decreased in HC rats compared with UC rats; D: UC rats had decreased alpha diversity compared with HC rats. After treatment, alpha diversity 
was increased in the UC-7 and UC-W groups. 
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Figure 9  The relative expression levels of IL-6, IL-10, IL-12, IL-17, IL-23, TNF-α, TNFR1 and TNFR2 in colon mucosa. HC: Healthy controls; UC: UC model 
group; UC-7: UC model with seven days of moxibustion; UC-14: UC model with fourteen days of moxibustion; UC-W: UC model with mesalazine gavage. The relative 
expression levels of IL-12 (P < 0.05), IL-6, IL-17, IL-23, TNF-α, TNFR1 and TNFR2 (P < 0.01) in the UC group were increased compared with the HC group. IL-10 (P 
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increases and IL­10 mRNA (P < 0.01) exhibited a sig­
nificant decrease in the UC rats compared with their 
expression levels in HC rats (Figure 9). We found signifi­
cantly lower levels of IL­17, IL­23, TNF­α, TNFR2 (P < 
0.01), IL­6, IL­12, and TNFR1 mRNA (P < 0.05) in the 
UC­7 group compared to the UC group. The relative 
expression levels of IL­6, IL­12, IL­17, IL­23 (P < 0.01), 
TNF­α and TNFR1 mRNA (P < 0.05) were also lower in 
the UC­14 group than in the UC group, and IL­10 mRNA 
was both higher in the UC­7 group (P < 0.01), the UC­14 
group (P < 0.01) and the UC­W group (P < 0.05) than 
in the UC group. However, no significant differences 
in the relative expression levels of TNFR2 mRNA were 
noted between the UC­14 and UC groups (P > 0.05). 
Significant decreases in IL­6, IL­17, IL­23, TNF­α, TNFR1, 
and TNFR2 mRNA (P < 0.01) were also noted in the 
UC­W group compared with the UC group. 
The levels of IL-2, IL-10, IL-12, IL-17, IL-23, IFN-γ, LPS, 
IgA, TGF-β, TNF-α, TNFR1 and TNFR2 in serum
As shown in Figure 10, we noted lower levels of IL­2, 
IL­10 (P < 0.01) and TGF­β (P < 0.05) and higher levels 
of IL­12 (P < 0.05), IL­17, IL­23, IFN­γ, LPS, IgA, TNF­α, 
TNFR1 and TNFR2 (P < 0.01) in the UC group compared 
with HC group. Interestingly, we also noted significantly 
higher levels of IL­2 (P < 0.01), IL­10 (UC­7, P < 0.05; 
UC­W and HC­7, P < 0.01) and TGF­β (UC­7 and UC­W, 
P < 0.05; HC­7, P > 0.05) in treatment groups than the 
UC group. Similarly, the levels of IL­17 (UC­7 and HC­7, P 
< 0.05; UC­W, P < 0.01), IL­23, IFN­γ, LPS, IgA, TNFR1, 
TNFR2 (P < 0.01), TNF­α (P < 0.05) in serum were lower 
in the UC­7 and UC­W groups. However, there were 
no significant differences in the level of IL­12 between 
the UC group and the UC­7 group and between the 
UC group and the UC­W group (P > 0.05). The results 
were not completely consistent with the PCR. ELISA 
is a quantitative method to detect proteins, and PCR 
is the detection of the target gene from the transcript 
level. Due to post­transcriptional and post­translation 
regulation, gene expression and protein expression do 
not necessarily correlate. 
DISCUSSION
In the last decade, several studies have revealed a 
strong association between gut microbiome dysbiosis 
and UC[17,43­45]. According to the traditional Chinese 
medicine theory, the Tianshu (ST25) acupoint is the Mu 
point of large intestine and can regulate gastrointestinal 
functions, and is usually used to treat abdominal pain 
and diarrhoea[46]. Moxibustion is an effective and safe 
treatment for UC, but the underlying mechanism remains 
unknown. Moxibustion treatment regulates intestinal 
flora and inhibits TNF­α and IL­12 expression in the 
colon tissues of UC rats, which can regulate the colonic 
immune response[30]. However, no study has investigated 
the effects of moxibustion on the intestinal flora using 
whole microbiome analysis. Therefore, we employed a 
16S rRNA amplicon sequencing approach to determine 
the effects of moxibustion treatment on the microbiome 
in a UC rat model. 
We found that moxibustion treatment increased 
Firmicutes abundance and decreased the abundance 
levels of Bacteroidetes and Proteobacteria. In terms 
of alpha diversity, HC­14 was more similar to HC than 
HC­7, which was confirmed by PCoA. In terms of alpha 
diversity, UC­14 was also more similar to UC than UC­7. 
This finding suggests that short­term (seven days) but 
not longer term (fourteen days) moxibustion treatment 
may significantly affect the gut microbiome. Overall, 
the relative abundance levels of beneficial bacteria were 
decreased, and the growth of several opportunistic 
pathogenic species was increased in the UC rats. 
We found that gut microbiome diversity was signifi­
cantly reduced in UC rats compared with healthy con­
trols, consistent with previous reports. The abundance 
levels of Firmicutes, Bacteroidetes and Proteobacteria 
Candidatus varied between treatment groups. In 
particular, Firmicutes was less abundant in UC rats. At 
the family level, this effect translated to reductions in 
host beneficial taxa, including Ruminococcaceae and 
Lactobacillaceae, which are closely associated with UC[47]. 
At the genus level, Lactobacillus, Bifidobacterium and 
Ruminococcus were decreased in UC rats, consistent 
with the literature[15,46]. Several studies have reported 
that Lactobacillus and Bifidobacterium played key roles 
in treating UC patients or rats by inhibiting Toll­like 
receptor 4 expression to reduce TNF­α expression[47] 
and enhancing anti­inflammatory cytokine IL­10 pro­
duction[48]. UC pathogenesis may be associated with the 
decreased levels of Lactobacillus and Bifidobacterium, 
which consequently led to increases in inflammatory 
cytokines and decreases in anti­inflammatory cyto­
kines. Lactobacillus and Bifidobacterium can down­
regulate inflammatory cytokines[49] and stimulate anti­
inflammatory cytokines, such as IL­10[50], which may 
protect the host from mucosal inflammation. Interestingly, 
we found that the expression levels of inflammatory 
cytokines, such as IL­6, IL­12, IL­17, IL­23, IFN­γ, 
TNF­α, TNFR1 and TNFR2, were increased and that anti­
inflammatory cytokine IL­10 and TGF­β expression was 
decreased in UC rats compared with HC rats. These 
results indicate that gut microbial variation may affect 
mucosal immunity through up­regulating inflammatory 
cytokines and down­regulating anti­inflammatory cyto­
kines. However, the specific relationship between the 
gut microbiome and mucosal immunity needs further 
investigation. After moxibustion treatment, the levels of 
these inflammatory cytokines were significantly decreased, 
and anti­inflammatory cytokines were increased. These 
results demonstrated that moxibustion treatment may 
repair intestinal mucosal by down­regulating inflammatory 
cytokines and up­regulating anti­inflammatory cytokines. 
In an animal model of colitis, butyrate­producing bacteria 
alleviated intestinal inflammation and necrosis in colitis 
rats[50]. UC patients have fewer butyrate­producing 
bacteria, such as Clostridium leptum and Clostridium 
coccoides[51,52], which is supported by our findings. 
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Figure 10  The levels of IL-2, IL-10, IL-12, IL-17, IL-23, IFN-γ, LPS, IgA, TGF-β, TNF-α, TNFR1 and TNFR2 in serum. HC: Healthy controls; UC: UC model group; 
UC-7: UC model with seven days of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with seven days of moxibustion. IL-2, IL-10 (P 
< 0.01) and TGF-β (P < 0.05) were lower and IL-12 (P < 0.05), IL-17, IL-23, IFN-γ, LPS, IgA, TNF-α, TNFR1 and TNFR2 (P < 0.01) were higher in the UC group 
compared with the HC group. The levels of IL-2 (P < 0.01), IL-10 (UC-7, P < 0.05, UC-W and HC-7, P < 0.01) and TGF-β (UC-7 and UC-W, P < 0.05, HC-7, P > 0.05) 
were higher in the treatment groups than the UC group. The levels of IL-17 (UC-7 and HC-7, P < 0.05, UC-W, P < 0.01), IL-23, IFN-γ, LPS, IgA, TNFR1, TNFR2 (P < 
0.01), and TNF-α (P < 0.05) in serum were lower in the UC-7 and UC-W groups. However, there were no significant differences in the level of IL-12 between the UC 
group and the UC-7 group and between the UC group and the UC-W group (P > 0.05). aP < 0.05, bP < 0.01 vs the HC group. cP < 0.05, dP < 0.01 vs the UC group.
In UC rats, both moxibustion and mesalazine gavage 
for seven days led to increases in microbial diversity. 
Several studies have reported that mesalazine can 
improve the clinical symptoms and colon mucosal condi­
tion in UC patients[53,54]. These results demonstrate that 
moxibustion could potentially be used as an alternative 
treatment to mesalazine. It is not clear why the alpha 
diversity was decreased in UC rats treated with moxi­
bustion for fourteen days. It is possible that moxibustion 
is not suitable for long­term treatment of UC, and deter­
mining whether moxibustion has side effects requires 
further study. PCoA analysis showed that UC rats had 
distinct microbiome profiles compared with HC rats, 
and an increased similarity in PCoA axis scores was 
noted between the HC and UC­14 groups. These results 
indicate that moxibustion could possibly decrease distinct 
bacteria, such as opportunistic pathogens. 
High­throughput sequencing offers a new tool for 
studying the effect of moxibustion on the gut microbiome 
and its mechanism of action. Here, we report reduced 
diversity, gut microbial dysbiosis, increased inflammatory 
cytokines and decreased anti­inflammatory cytokines in 
DSS­induced colitis rats and show that these effects could 
be alleviated by moxibustion treatment. Our findings 
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suggest that moxibustion exerts its therapeutic effect 
by modulating the microbiome and intestinal mucosal 
immunity. Bacterial functions possibly associated with 
moxibustion treatment include ascorbate and aldarate 
metabolism and amino acid metabolism.
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Research background
The aetiology and pathogenesis of ulcerative colitis (UC) are not clear. In recent 
years, there has been growing evidence that the gut microbiota has a key role 
in the development of UC. Our previous study has shown that there are an 
imbalanced states of the beneficial bacteria Bifidobacterium, Lactobacillus, 
and harmful bacteria E. coli and Fusobacterium in the intestine of UC rats, 
and moxibustion can regulate the balance of beneficial bacteria and harmful 
bacteria in the intestine of UC rats. 
Research motivation
Many studies have confirmed the efficacy of moxibustion in UC, however, the 
role of gut microbiota in the pathogenesis of UC and the role of moxibustion in 
the regulation of the UC gut microbiota remain unclear.
Research objectives
The aim of this work is to investigate the effect and mechanism of moxibustion 
on gut microbiota in UC rats.
Research methods
UC was induced with 4% DSS in drinking water for seven consecutive days. 
Moxibustion was applied to the Tianshu (ST25, bilateral). Haematoxylin 
and eosin staining was assessed to evaluate the changes in the colon 
histopathology. Gut microbiome profiling was conducted by 16S rRNA amplicon 
sequencing, and PCR and ELISA determined the expression of inflammatory 
cytokines. 
Research results
Compared with the healthy controls (HC) group, the UC group had increased 
histopathological scores. After treatment, the scores were decreased in the 
UC-7, UC-14, UC-W, HC-7 and HC-14 groups compared with those in the UC 
group. The relative abundance of some of the bacteria in the UC group was 
changed at both the phylum, family and genus level. In addition, UC rats had 
reduced alpha diversity, which all could be alleviated by moxibustion therapy. 
Moxibustion can significantly reduce the levels of pro-inflammatory cytokines 
IL-6, IL-12, IL-17, IL-23, IFN-γ, LPS, TNF-α, TNFR1 and TNFR2 and increase 
anti-inflammatory cytokines IL-2 and TGF-β in rats with ulcerative colitis and 
reduce the intestinal inflammation.
Research conclusions
Our findings suggest that moxibustion exerts its therapeutic effect by modu-
lating the microbiome and intestinal mucosal immunity.
Research perspectives
The present study may provide a certain experimental basis and scientific basis 
for the clinical curative effect of the treatment of UC.
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